Apyx Medical Pursues Funding Amid Body Contouring Market Growth

NEW YORK, NY – November 17, 2025 – Apyx Medical Corporation (Nasdaq: APYX) announced plans to raise capital through a public offering of common stock, a move signaling continued investment in its Helium Plasma Platform Technology and expansion within the burgeoning surgical aesthetics market. While details regarding the size and pricing of the offering remain undisclosed, the company’s recent financial performance suggests a strategic move to capitalize on growing demand for minimally invasive procedures.

Navigating a Growing Market

Apyx Medical’s technology, marketed under the Renuvion and AYON Body Contouring System brands for cosmetic surgery and J-Plasma for hospital surgical use, is positioned within a sector experiencing significant growth. The body contouring market, in particular, has benefited from increased consumer interest in non-invasive and minimally invasive procedures, fueled by societal trends and advancements in technology. According to industry sources, this sector is expected to maintain a healthy growth trajectory in the coming years.

“The market is definitely seeing a shift towards these less invasive options,” notes one analyst, speaking anonymously. “Consumers are looking for effective treatments with shorter recovery times, and companies like Apyx Medical are well-positioned to meet that demand.”

Recent launches, such as the commercial release of the AYON Body Contouring System in the U.S. in September, demonstrate Apyx Medical’s commitment to innovation and market penetration. The company has also filed for further FDA clearance to expand the capabilities of the system. These advancements are supported by positive early customer reception and growing pre-sales numbers.

Recent Financial Performance Fuels Expansion

Apyx Medical’s recent financial results showcase a promising trajectory, potentially providing a strong foundation for the stock offering. The company reported third-quarter earnings that exceeded analyst expectations, with revenue reaching $12.9 million, a 12% increase year-over-year. Gross margins also improved to 64.4%, and net losses narrowed significantly.

“We’ve seen a really positive trend in revenue and margin improvement,” a company source stated, speaking on background. “This performance is a direct result of successful product launches and strong execution of our commercial strategy.”

While the company still operates at a loss, the narrowing deficit and increased revenue suggest a path toward profitability. The positive financial performance is also supported by a healthy balance sheet, with a current ratio of 4.44 indicating sufficient liquidity to meet short-term obligations. The company’s recent increase in full-year 2025 revenue guidance to $50.0-$52.0 million further reinforces this positive outlook.

However, the company acknowledges the challenges inherent in the medical device industry, including supply chain disruptions and the need for ongoing investment in research and development. Proceeds from the public offering are likely to be allocated towards these areas, as well as market expansion and general corporate purposes.

Analyst Sentiment and Investor Outlook

Following the release of its third-quarter earnings, Apyx Medical received an upgrade from Citizens, moving its stock rating from Market Perform to Market Outperform with a price target of $8.00. The upgrade reflects increased confidence in the company's growth prospects and the potential of its AYON system.

Despite this positive sentiment, the announcement of the public offering led to a slight dip in the stock price post-market. This reaction is not uncommon, as investors often view stock offerings as a potential dilution of existing shares. However, the long-term outlook for Apyx Medical remains positive, particularly given the company’s strong financial performance and strategic positioning within the growing surgical aesthetics market.

The company’s ability to successfully execute its growth plans, navigate potential challenges, and deliver on its financial objectives will be key to sustaining investor confidence and driving long-term value.